Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 6, 2010, Pages 2575-2582

  Sugaya, Norio ^a   Ohashi, Yasuo ^b  

^a Keiyu Hospital   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CS 8958; LANINAMIVIR OCTANOATE; LONG ACTING DRUG; OSELTAMIVIR; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG;

ABNORMAL BEHAVIOR; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYING; DELIRIUM; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HUMAN; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; VOMITING;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MALE; NEURAMINIDASE; OSELTAMIVIR; TREATMENT OUTCOME; VIRUS SHEDDING; ZANAMIVIR;

EID: 77952611625     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01755-09     Document Type: Article

References (24)

1. Behrens, B., and G. Kärber. 1935. Wie sind Rehenversuche für biologishe Auswertungen am zweckmäsigsten anzuordnen? Naunyn Schmiedebergs Arch. Pharmakol. Exp. Pathol. 177:377-388.
2. Dominguez-Cherit, G., S. E. Lapinsky, A. E. Macias, et al. 2009. Critically ill patients with 2009 influenza A (H1N1) in Mexico. JAMA 302:1880-1887.
3. Guo, L., R. J. Garten, A. S. Foust, et al. 2009. Rapid identification of oseltamivir-resistant influenza A (H1N1) viruses with H274Y mutation by RT-PCR/restriction fragment length polymorphism assay. Antiviral Res. 82:29-33.
4. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 1996. ICH harmonized tripartite guideline: guideline for good clinical practice. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland. http://www.ich.org /cache/compo/276-254-1.html.
5. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 1998. ICH harmonized tripartite guideline: statistical principles for clinical trials. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland. http://www.ich.org /cache/compo/276-254-1. html.
6. Ishizuka, H., S. Yoshiba, H. Okabe, and K. Yoshihara. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. J. Clin. Pharmacol., in press.
7. Itoh, Y., K. Shinya, M. Kiso, et al. 2009. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460:1021-1025.
8. Jain, S., L. Kamimoto, A. M. Bramley, et al. 2009. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June. N. Engl. J. Med. 361:1935-1944.
9. Kawai, N., H. Ikematsu, N. Iwaki, et al. 2009. Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation. J. Infect. 59:207-212.
10. Koyama, K., M. Takahashi, M. Oitate, et al. 2009. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long retention profile in the mouse respiratory tract. Antimicrob. Agents Chemother. 53:4845-4851.
11. Kubo, N., H. Ikematsu, S. Nabeshima, et al. 2003. Evaluation of an immunochromatography test kit for rapid diagnosis of influenza. Kansenshogaku Zasshi 77:1007-1014.
12. Kubo, S., T. Tomozawa, M. Kakuta, A. Tokumitsu, and M. Yamashita. 2010. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob. Agents Chemother. 54:1256-1264.
13. Reichert, T. A., N. Sugaya, D. S. Fedson, W. P. Glezen, L. Simonsen, and M. Tashiro. 2001. The Japanese experience with vaccinating schoolchildren against influenza. N. Engl. J. Med. 344:889-896.
14. Shun-Shin, M., M. Thompson, C. Heneghan, R. Perera, A. Harnden, and D. Mant. 2009. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials. BMJ 339:b3172. doi:10.1136/bmj.b3172.
15. Sugaya, N., K. Mitamura, M. Nirasawa, and K. Takahashi. 2000. The impact of winter epidemics of influenza and respiratory syncytial virus on paediatric admissions to an urban general hospital. J. Med. Virol. 60:102-106.
16. Sugaya, N., K. Mitamura, M. Yamazaki, et al. 2007. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin. Infect. Dis. 44:197-202.
17. Sugaya, N., K. Nerome, M. Ishida, et al. 1992. Impact of influenza virus infection as a cause of pediatric hospitalization. J. Infect. Dis. 165:373-375.
18. Sugaya, N., D. Tamura, M. Yamazaki, et al. 2008. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin. Infect. Dis. 47:339-345.
19. Whitley, R. J., F. G. Hayden, K. S. Reisinger, et al. 2001. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20:127-133.
20. World Health Organization. 2009. Influenza A(H1N1) virus resistance to oseltamivir-2008/2009 influenza season, northern hemisphere. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/disease /influenza/H1N1webupdate20090318%20ed-ns.pdf.
21. World Health Organization. 2009. World now at the start of 2009 influenza pandemic. June 2009. World Health Organization, Geneva, Switzerland. http://www .who.int/mediacentre/news/statements/2009/h1n1-pandemic-phase6-20090611/en /index.html.
22. World Health Organization. 2010. Pandemic (H1N1) 2009-update 86. World Health Organization, Geneva, Switzerland. http://www.who.int/csr /disease/swineflu/laboratory05-02-2010/en/index.html.
23. Yamashita, M., T. Tomozawa, M. Kakuta, A. Tokumitsu, H. Nasu, and S. Kubo. 2009. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob. Agents Chemother. 53:186-192.
24. Yamazaki, M., K. Mitamura, K. Kimura, et al. 2001. Clinical evaluation of an immunochromatography test for rapid diagnosis of influenza. Kansenshogaku Zasshi 75:1047-1053.